SXTC Stock Analysis: Buy, Sell, or Hold?
SXTC - China SXT Pharmaceuticals, Inc. Ordinary Shares
$0.05
-0.03 (-34.93%)
▼
5d:
-30.96%
30d:
-98.11%
90d:
-25.55%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Oct 07, 2026
0d
Get Alerted When SXTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SXTC is down 31.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SXTC is down 31.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SXTC is currently trading at $0.05, which is considered oversold relative to its 30-day fair value range of $0.39 to $2.76.
Technical Outlook: Technically, SXTC is showing sideways momentum. The price is currently testing key support at $0.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 34.9% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SXTC is showing sideways momentum. The price is currently testing key support at $0.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 34.9% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.39 -
$2.76
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
68.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (58/100)
- BEARISH: Downward momentum (-34.9%)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.39 -
$2.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.06
Resistance Level
$0.46
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Revenue Growth (YoY)
-43.9%
Earnings Growth (YoY)
42.6%
Share & Embed Analysis
Last updated: October 22, 2026 12:48 PM ET
Data refreshes hourly during market hours. Next update: 1:48 PM
Data refreshes hourly during market hours. Next update: 1:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SXTC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
